Viz.ai, a US-based brain scanning technology developer backed by internet and technology conglomerate Alphabet, has secured $71m in series C funding.
Growth equity firm Insight Partners and venture capital firm Scale Venture Partners co-led the round, which included CRV, Greenoaks Capital, Innovation Endeavors, Kleiner Perkins, Susa Ventures and Threshold Ventures. The company has raised $150m in total since it was founded in 2016.
Viz has built artificial intelligence (AI) and machine learning-equipped healthcare diagnosis software. Its lead product, Viz LVO, helps care providers detect stroke patients in a timely manner.
The cash will be used to improve the company’s AI technology to enable it to cover other acute care areas including heart, lungs and trauma treatments, as well as to expand the availability of its products globally.
Chris Mansi, Viz’s co-founder and CEO, said: “The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system both in the United States and Europe.”
GV, a corporate venturing subsidiary of Alphabet, took part in a $50m series B round for Viz in late 2019 that was led by Greenoaks Capital and which also featured CRV, Kleiner Perkins and Threshold Ventures.
Kleiner Perkins (then known as Kleiner Perkins Caufield & Byers) had led the company’s $21m series A round for Viz the year before, investing together with GV.
DHVC and Innovation Endeavors co-led a $7.3m round closed by Viz in 2017, according to regulatory filings, with contributions from AME Cloud Ventures and Susa Ventures. Seedcamp is also among its shareholders.
